ketanserin has been researched along with Hypertrophy, Right Ventricular in 4 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Hypertrophy, Right Ventricular: Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| " During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day)." | 3.72 | Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. ( Adnot, S; Eddahibi, S; Hamon, M; Marcos, E; Nosjean, A; Pham, MH; Raffestin, B, 2003) |
| "Treatment with ketanserin attenuated bleomycin-induced PH (increased RVSP and RVH) and pulmonary vascular remodeling (decreased vessel density and increased muscularization of small vessels)." | 1.48 | Serotonin 2A receptor inhibition protects against the development of pulmonary hypertension and pulmonary vascular remodeling in neonatal mice. ( Delaney, C; Fisher, S; Maltzahn, J; Nozik-Grayck, E; Sherlock, L; Wright, C, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delaney, C | 1 |
| Sherlock, L | 1 |
| Fisher, S | 1 |
| Maltzahn, J | 1 |
| Wright, C | 1 |
| Nozik-Grayck, E | 1 |
| Liu, Y | 1 |
| Tian, H | 1 |
| Yan, X | 1 |
| Fan, F | 1 |
| Wang, W | 1 |
| Han, J | 1 |
| Marcos, E | 1 |
| Adnot, S | 1 |
| Pham, MH | 1 |
| Nosjean, A | 1 |
| Raffestin, B | 1 |
| Hamon, M | 1 |
| Eddahibi, S | 1 |
| Deuchar, GA | 1 |
| Hicks, MN | 1 |
| MacLean, MR | 1 |
4 other studies available for ketanserin and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Serotonin 2A receptor inhibition protects against the development of pulmonary hypertension and pulmonary vascular remodeling in neonatal mice.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Bleomycin; Bronchopulmonary Dysplasia; Hyper | 2018 |
Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension.
Topics: Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Familial Primary Pu | 2013 |
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Carrier Proteins; Chronic Disease; Citalopram; Disease Models, Animal | 2003 |
The role of 5-hydroxytryptamine in the control of pulmonary vascular tone in a rabbit model of pulmonary hypertension secondary to left ventricular dysfunction.
Topics: Animals; Aorta; Blood Pressure; Cardiac Output; Disease Models, Animal; Heart Rate; Hypertension, Pu | 2005 |